Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1504 participants.
Also called NCT01159600
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,504 participants
- Registry
-
NCT01159600 -
2009-016258-41
-
- Other papers using this trial's data
- Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- United States, Canada, China, France, Germany, India, Mexico, Slovakia, Slovenia, South Korea, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01159600. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2014-06-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo identical to BI 10773 high dose
- Intervention (Drug)
- Placebo identical to BI 10773 low dose
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo identical to BI 10773 low dose
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo identical to BI 10773 high dose
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01159600- Content hash
472b3619b759d7b3cb4ea0440c90cf0a5090e62dbf5c786a7f530cf49f669661